Related Experiment Video
Updated: Aug 14, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Decreased MMP-9 production in primary progressive multiple sclerosis patients
J Sastre-Garriga1, M Comabella, L Brieva
1Unitat de Neuroimmunologia Clínica, Hospital Vail d'Hebron, Barcelona, Espanya. jsastre@hg.vhebron.es
Background:
An increase in MMP-9 levels has been found in relapsing-remitting (RR) multiple sclerosis (MS) showing correlation with magnetic resonance (MR) parameters mainly during relapses. However, data regarding primary progressive (PP) MS is scarce.
Objectives:
To determine both the pro and active forms of MMP-9 in PPMS and transitional progressive (TP) MS, RRMS and healthy controls (HC), and to assess the relationship between MMP-9 levels and clinical and radiological variables in PP/TPMS.
Methods:
73 patients with PP/TPMS, 50 RRMS and 43 HC were studied. Levels of pro and active forms of MMP-9 in serum were measured with ELISA. EDSS and MSFC scores were recorded and T2- and T1-weighted MR scans were obtained at the time of blood sampling and one and two years later for PP/TP MS cases.
Results:
MMP-9 levels were 202.27 ng/ml for PP/TPMS, 242.20 ng/ml for RRMS and 274.49 ng/ml for HC. MMP-9 levels were significantly lower in PP/TPMS compared to RRMS (P= 0.026) and HC (P= 0.001). No significant correlations were found between MMP-9 levels and clinical scores or radiological parameters.
Conclusions:
These results point to different regulatory mechanisms of MMP-9 production and/or activity between PP/TPMS and RRMS.
Related Concept Videos
Role of Matrix Metalloproteases in Degradation of ECM
A...
Multiple Sclerosis l: Introduction

